[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-fda-peptide-review-2026-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":268,"_id":269,"_source":270,"_file":271,"_stem":272,"_extension":273},"\u002Fblog\u002Fzh\u002Ffda-peptide-review-2026","zh",false,"","2026年7月，FDA就BPC-157、TB-500等七种肽召开听证会","以下内容属于一般性科普，不构成医疗建议，也不是在建议你去获取或使用任何物质。它只是在解释一个监管流程，仅此而已。下文提到的几种物质并未获批用于人体。","监管","tabler:building-bank","#3E7BB6","2026-07-01","2026年7月","6 min","myPeptides Team","\u002Fassets\u002Ffda_peptides_hero.png",{"type":19,"children":20,"toc":259},"root",[21,28,44,51,56,110,115,124,130,135,140,145,150,155,160,180,185,190,211,216,221],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,42],{"type":27,"value":32},"一句话概括：2026年7月23日和24日，FDA下属的药房配制咨询委员会（PCAC）将开会，商定要就七种早已被很多人挂在嘴边的肽——包括BPC-157和TB-500——提出什么建议。问题本身范围很窄，但份量不轻：这些物质该不该被列入503A条款下的\"原料药清单\"，而正是这份清单，决定了配制药房能否合法地为患者制备它们。委员会只负责提建议，最终拍板的还是FDA。更多细节可见",{"type":22,"tag":34,"props":35,"children":39},"a",{"href":36,"rel":37},"https:\u002F\u002Fwww.fda.gov\u002Fadvisory-committees\u002Fadvisory-committee-calendar\u002Fjuly-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",[38],"nofollow",[40],{"type":27,"value":41},"FDA官方的会议页面",{"type":27,"value":43},"。",{"type":22,"tag":45,"props":46,"children":48},"h2",{"id":47},"有哪几种肽什么时候审",[49],{"type":27,"value":50},"有哪几种肽，什么时候审",{"type":22,"tag":23,"props":52,"children":53},{},[54],{"type":27,"value":55},"议程分成两天。",{"type":22,"tag":57,"props":58,"children":59},"table",{},[60,79],{"type":22,"tag":61,"props":62,"children":63},"thead",{},[64],{"type":22,"tag":65,"props":66,"children":67},"tr",{},[68,74],{"type":22,"tag":69,"props":70,"children":71},"th",{},[72],{"type":27,"value":73},"日期",{"type":22,"tag":69,"props":75,"children":76},{},[77],{"type":27,"value":78},"审议的肽",{"type":22,"tag":80,"props":81,"children":82},"tbody",{},[83,97],{"type":22,"tag":65,"props":84,"children":85},{},[86,92],{"type":22,"tag":87,"props":88,"children":89},"td",{},[90],{"type":27,"value":91},"2026年7月23日",{"type":22,"tag":87,"props":93,"children":94},{},[95],{"type":27,"value":96},"BPC-157、KPV、TB-500、MOTS-c",{"type":22,"tag":65,"props":98,"children":99},{},[100,105],{"type":22,"tag":87,"props":101,"children":102},{},[103],{"type":27,"value":104},"2026年7月24日",{"type":22,"tag":87,"props":106,"children":107},{},[108],{"type":27,"value":109},"Emideltide（DSIP）、Semax、Epitalon",{"type":22,"tag":23,"props":111,"children":112},{},[113],{"type":27,"value":114},"如果你觉得这些名字很眼熟，那是因为它们正是\"科研用肽\"以及恢复\u002F抗衰圈子的招牌角色。到目前为止，其中大多数都卡在一个不上不下的法律灰色地带里——而这场会议要谈的，恰恰就是这个。",{"type":22,"tag":23,"props":116,"children":117},{},[118],{"type":22,"tag":119,"props":120,"children":123},"img",{"alt":121,"src":122},"放大镜下的七支西林瓶，旁边放着一块审查用的记录板","\u002Fassets\u002Ffda_peptides_seven.png",[],{"type":22,"tag":45,"props":125,"children":127},{"id":126},"_503a清单到底是什么",[128],{"type":27,"value":129},"503A清单到底是什么",{"type":22,"tag":23,"props":131,"children":132},{},[133],{"type":27,"value":134},"配制药房为个别患者定制药物。但它们不能拿随便什么原料就上手配。对于那些还不是已获批药物成分的原料药来说，一般都得先进入FDA的503A原料药清单，药剂师才能合法地拿它来配药。上了清单，就意味着有一条合法途径，可以由持牌药房来制备它。没上清单，就没有这条路；于是在市面上流通的，就变成了那些贴着\"仅供科研使用\"标签的灰色市场货——既没有合法途径，也没有任何质量保证。",{"type":22,"tag":23,"props":136,"children":137},{},[138],{"type":27,"value":139},"所以这场讨论不是在争这些肽到底有没有用。它要回答的，是一个窄得多的行政问题：从安全性和标准来看，是否有足够充分的理由，让受监管的药房去配制它们。",{"type":22,"tag":45,"props":141,"children":143},{"id":142},"当初它们为什么会被点名",[144],{"type":27,"value":142},{"type":22,"tag":23,"props":146,"children":147},{},[148],{"type":27,"value":149},"这七种肽走到今天这一步并非偶然。它们此前被FDA归进了\"第二类\"（Category 2）那一档，意思是监管方对它们存有明显的安全疑虑，或者掌握的信息不足。被送到PCAC这一步，是把这些问题摆到台面上公开讨论的正式程序：呈报数据、请专家投票给出建议。结果两头都有可能，而且委员会的投票只是建议，不是最终定论。",{"type":22,"tag":45,"props":151,"children":153},{"id":152},"结果会改变什么",[154],{"type":27,"value":152},{"type":22,"tag":23,"props":156,"children":157},{},[158],{"type":27,"value":159},"大体上，对任何一种肽而言，可能出现三种走向：",{"type":22,"tag":161,"props":162,"children":163},"ul",{},[164,170,175],{"type":22,"tag":165,"props":166,"children":167},"li",{},[168],{"type":27,"value":169},"建议列入清单。一条合法的配制途径就此打开，长期来看，这往往意味着产品更稳定、达到药房级水准，也让人少了几分去碰灰色市场的理由。",{"type":22,"tag":165,"props":171,"children":172},{},[173],{"type":27,"value":174},"不予列入。维持现状：没有合法的配制途径，网上卖的那些依旧是未获批、不受监管的货。",{"type":22,"tag":165,"props":176,"children":177},{},[178],{"type":27,"value":179},"暂缓，等更多数据。当正反两边的证据都不足时，这种情况很常见。",{"type":22,"tag":23,"props":181,"children":182},{},[183],{"type":27,"value":184},"对读者来说，真正该记住的不是\"赶紧买\"或\"离远点\"，而是：这几种肽脚下的法律地基，可能在几周之内就发生变化，值得盯着看，别想当然地以为今天的局面会一直不变。这一轮还多了一层政治因素：委员会的人员构成，再加上一股要求放宽准入的更大声浪，已经引来公众争论——读这类报道时，最好用你对待任何游说时的那种怀疑眼光去看。",{"type":22,"tag":45,"props":186,"children":188},{"id":187},"该盯着看什么",[189],{"type":27,"value":187},{"type":22,"tag":23,"props":191,"children":192},{},[193,195,201,203,209],{"type":27,"value":194},"会议在7月23到24日举行。建议通常很快就会出来；FDA真正的决定则可能要等更久。等投票结果和任何决定公开后，我们会更新这篇文章。如果你想先搞清楚背后的法律背景，可以看",{"type":22,"tag":34,"props":196,"children":198},{"href":197},"\u002Fare-peptides-legal",[199],{"type":27,"value":200},"肽是否合法",{"type":27,"value":202},"；如果你还不清楚这些化合物到底是什么，那就从",{"type":22,"tag":34,"props":204,"children":206},{"href":205},"\u002Fwhat-are-peptides",[207],{"type":27,"value":208},"什么是肽",{"type":27,"value":210},"看起。",{"type":22,"tag":23,"props":212,"children":213},{},[214],{"type":27,"value":215},"不管委员会最后怎么决定，\"仅供科研使用\"这个标签，改变不了一种物质本身到底是什么，本文也绝不是在建议你去用它。这篇文章讲的是规则，不是放行的绿灯。",{"type":22,"tag":45,"props":217,"children":219},{"id":218},"参考来源",[220],{"type":27,"value":218},{"type":22,"tag":161,"props":222,"children":223},{},[224,235,247],{"type":22,"tag":165,"props":225,"children":226},{},[227,229],{"type":27,"value":228},"FDA，",{"type":22,"tag":34,"props":230,"children":232},{"href":36,"rel":231},[38],[233],{"type":27,"value":234},"药房配制咨询委员会会议，2026年7月23–24日",{"type":22,"tag":165,"props":236,"children":237},{},[238,240],{"type":27,"value":239},"Drug Topics，",{"type":22,"tag":34,"props":241,"children":244},{"href":242,"rel":243},"https:\u002F\u002Fwww.drugtopics.com\u002Fview\u002Ffda-set-to-review-peptide-access-for-compounding-pharmacies",[38],[245],{"type":27,"value":246},"FDA将审议配制药房的肽类获取问题",{"type":22,"tag":165,"props":248,"children":249},{},[250,252],{"type":27,"value":251},"Lengea Law，",{"type":22,"tag":34,"props":253,"children":256},{"href":254,"rel":255},"https:\u002F\u002Flengealaw.com\u002Ffda-puts-bpc-157-tb-500-and-5-other-peptides-under-the-microscope-what-prescribers-need-to-know-about-the-503a-review\u002F",[38],[257],{"type":27,"value":258},"FDA把BPC-157、TB-500等七种肽送上503A的显微镜",{"title":7,"searchDepth":260,"depth":260,"links":261},2,[262,263,264,265,266,267],{"id":47,"depth":260,"text":50},{"id":126,"depth":260,"text":129},{"id":142,"depth":260,"text":142},{"id":152,"depth":260,"text":152},{"id":187,"depth":260,"text":187},{"id":218,"depth":260,"text":218},"markdown","content:blog:zh:fda-peptide-review-2026.md","content","blog\u002Fzh\u002Ffda-peptide-review-2026.md","blog\u002Fzh\u002Ffda-peptide-review-2026","md"]